Lavipharm S.A. (ATH:LAVI)
Greece flag Greece · Delayed Price · Currency is EUR
1.420
+0.040 (2.90%)
Apr 9, 2026, 5:19 PM EET

Lavipharm Statistics

Total Valuation

Lavipharm has a market cap or net worth of EUR 239.54 million. The enterprise value is 267.18 million.

Market Cap239.54M
Enterprise Value 267.18M

Important Dates

The next confirmed earnings date is Thursday, April 23, 2026.

Earnings Date Apr 23, 2026
Ex-Dividend Date n/a

Share Statistics

Lavipharm has 168.69 million shares outstanding.

Current Share Class 168.69M
Shares Outstanding 168.69M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) n/a
Owned by Institutions (%) 2.21%
Float n/a

Valuation Ratios

The trailing PE ratio is 39.99.

PE Ratio 39.99
Forward PE n/a
PS Ratio 3.83
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings 44.60
EV / Sales 4.27
EV / EBITDA 20.27
EV / EBIT 28.58
EV / FCF n/a

Financial Position

Current Ratio n/a
Quick Ratio n/a
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage 5.06

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) n/a
Return on Invested Capital (ROIC) 15.03%
Return on Capital Employed (ROCE) n/a
Weighted Average Cost of Capital (WACC) 8.94%
Revenue Per Employee 221,929
Profits Per Employee 21,241
Employee Count282
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, Lavipharm has paid 2.45 million in taxes.

Income Tax 2.45M
Effective Tax Rate 32.69%

Stock Price Statistics

The stock price has increased by +91.38% in the last 52 weeks. The beta is 0.85, so Lavipharm's price volatility has been lower than the market average.

Beta (5Y) 0.85
52-Week Price Change +91.38%
50-Day Moving Average 1.27
200-Day Moving Average 0.95
Relative Strength Index (RSI) 67.29
Average Volume (20 Days) 269,406

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Lavipharm had revenue of EUR 62.58 million and earned 5.99 million in profits.

Revenue62.58M
Gross Profit 30.31M
Operating Income 9.35M
Pretax Income 7.50M
Net Income 5.99M
EBITDA 13.18M
EBIT 9.35M
Earnings Per Share (EPS) n/a
Full Income Statement

Balance Sheet

Cash & Cash Equivalents n/a
Total Debt n/a
Net Cash n/a
Net Cash Per Share n/a
Equity (Book Value) n/a
Book Value Per Share n/a
Working Capital n/a
Full Balance Sheet

Cash Flow

Operating Cash Flow n/a
Capital Expenditures n/a
Depreciation & Amortization 3.83M
Net Borrowing n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 48.42%, with operating and profit margins of 14.94% and 9.57%.

Gross Margin 48.42%
Operating Margin 14.94%
Pretax Margin 11.99%
Profit Margin 9.57%
EBITDA Margin 21.06%
EBIT Margin 14.94%
FCF Margin n/a

Dividends & Yields

This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 1.41%.

Dividend Per Share 0.02
Dividend Yield 1.41%
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield 1.45%
Earnings Yield 2.50%
FCF Yield n/a
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.

Last Split Date Aug 1, 2022
Split Type Reverse
Split Ratio 0.3333333333

Scores

Altman Z-Score n/a
Piotroski F-Score 2